## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.3% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Amundi Sells 401,103 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251209T083506 | Neutral | Relevance: 98%
- Amundi significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by selling 401,103 shares, decreasing its holdings by 38.7% in the second quarter. Despite this, other institutional investors have increased their positions in the medical equipment provider. Analysts currently rate Zimmer Biomet with a consensus "Hold" and a target price of $109.00.

**2. Gamco Investors INC. ET AL Buys 45,164 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251208T114459 | Neutral | Relevance: 97%
- Gamco Investors INC. ET AL increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.5%, purchasing 45,164 shares, bringing its total holdings to 245,955 shares valued at approximately $22.43 million. Other institutional investors also adjusted their positions in the medical equipment provider. Analysts currently have a mixed outlook on ZBH, with a consensus "Hold" rating and an average price target of $109.00, although recent target adjustments varied.

**3. DexCom (Nasdaq:DXCM) - Stock Analysis**
- Source: Simply Wall Street | 20251208T000759 | Neutral | Relevance: 63%
-  DexCom (DXCM) is a medical device company specializing in continuous glucose monitoring systems, with a market cap of US$25.6 billion. The stock is currently trading 47.8% below its estimated fair value, with analysts forecasting a 20.36% annual earnings growth and a 27.8% potential stock price increase. Recent news includes new educational offerings, FDA clearances for G7 and integrated basal insulin dosing, and executive stock transactions.

**4. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: The AI Journal | 20251209T150812 | Somewhat-Bullish | Relevance: 62%
- The AI-powered medical devices market is projected to reach $59.84 billion by 2032, growing at a CAGR of 18.26% from $15.64 billion in 2024. This growth is driven by technological integration and expanded adoption across clinical environments, with key players including GE HealthCare Technologies, Siemens Healthineers, and Philips. The report highlights AI's role in diagnostics, monitoring, and treatment, emphasizing its impact on medical workflows and operational efficiency.

**5. Solventum Corporation (SOLV): A Bull Case Theory**
- Source: Finviz | 20251209T200815 | Neutral | Relevance: 62%
- This article summarizes a bull thesis on Solventum Corporation (SOLV), a healthcare company recently spun off from 3M. Despite initial high debt, the company has deleveraged significantly through asset sales and is now positioned for a turnaround under strong leadership. The thesis highlights attractive valuation, clear growth targets, and a favorable risk-reward profile for patient investors, while acknowledging risks like potential PFAS litigation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Canaccord Genui | $93 | $101 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Canaccord Genui | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($0.00M) |
| Sells | 2 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 6.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 10.8x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.3B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 10.8 |
| Current P/E | 11.3 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -3.3% (minimal 5-day change). Below STRENGTH zone by 6.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.93x), long-term trend not supportive. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.29% (CS: 22) | Weak |
| RSI_14 | 44.5 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 0.960x | Below |
| vs SMA200 | 0.934x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $92.27
- **Stop Loss:** $87.57 (5.1% risk)
- **Target:** $96.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 63
- **Position Value:** $5,813.01
- **Portfolio %:** 5.81%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*